Table 1. Baseline characteristics of the HCC population according to treatment options (LA vs TACE).
| LA group | TACE group | p value | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Male/Female | 29/12 | (70.7/29.3) | 29/12 | (70.7/29.3) | 1 |
| Age, years, median (range) | 72 (54–88) | 72 (49–86) | 0.603 | ||
| BMI, median (range) | 27.3 (17.2–36.6) | 26.1 (17.7–32.0) | 0.136 | ||
| Liver disease etiology | |||||
| HCV infection | 32 | 78.0 | 22 | 53.7 | 0.036 |
| HBV infection | 2 | 4.9 | 3 | 7.3 | 1 |
| Alcohol | 1 | 2.4 | 8 | 19.5 | 0.034 |
| Others | 6 | 14.7 | 8 | 19.5 | 1 |
| Comorbidities | |||||
| none | 13 | 31.7 | 16 | 39.0 | 0.508 |
| metabolic | 4 | 9.8 | 7 | 17.1 | |
| cardiovascular | 14 | 34.1 | 13 | 31.7 | |
| metabolic + cardiovascular | 9 | 22.0 | 5 | 12.2 | |
| pulmonary | 1 | 2.4 | 0 | 0.0 | |
| Child-Pugh class | |||||
| A | 34 | 82.9 | 37 | 90.2 | 0.519 |
| B | 7 | 17.1 | 4 | 9.8 | |
| BCLC stage | |||||
| A | 27 | 65.9 | 28 | 68.3 | 0.275 |
| B | 14 | 34.1 | 13 | 31.7 | |
| Tumour size, mm, median (range) | 46 (40–75) | 47 (40–76) | 0.16 | ||
| Nodule size >50 mm | 13 (31.7%) | 14 (34.1%) | 0.492 | ||